Literature DB >> 11513563

Dormancy in a model of murine B cell lymphoma.

J W Uhr1, R Marches.   

Abstract

A B cell lymphoma model of dormancy in mice was established by prior immunization to the B cell membrane immunoglobulin idiotype. The antibody to the idiotype was the major factor in inducing and maintaining dormancy and acted primarily as an agonist rather than via effector functions. CD8+ T cells synergized with anti-Id in inducing dormancy by secreting IFN-gamma. Cycling in the dormant population was reduced 3-5 fold, but each mouse contained approximately 10(6) tumor cells in its spleen, some of which were cycling, during the 1.5 years of observation. Thus, replication is balanced by cell death. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11513563     DOI: 10.1006/scbi.2001.0383

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  11 in total

1.  [F-18]-Fluoro-2-deoxy-D: -glucose positron emission tomography as a tool for early detection of immunotherapy response in a murine B cell lymphoma model.

Authors:  Coralie Chaise; Emmanuel Itti; Yolande Petegnief; Evelyne Wirquin; Christiane Copie-Bergman; Jean-Pierre Farcet; Marie-Hélène Delfau-Larue; Michel Meignan; Jean-Noël Talbot; Valérie Molinier-Frenkel
Journal:  Cancer Immunol Immunother       Date:  2006-12-14       Impact factor: 6.968

2.  The problem of cancer dormancy: understanding the basic mechanisms and identifying therapeutic opportunities.

Authors:  Julio A Aguirre-Ghiso
Journal:  Cell Cycle       Date:  2006-08-15       Impact factor: 4.534

Review 3.  Dormancy in solid tumors: implications for prostate cancer.

Authors:  Nazanin S Ruppender; Colm Morrissey; Paul H Lange; Robert L Vessella
Journal:  Cancer Metastasis Rev       Date:  2013-12       Impact factor: 9.264

Review 4.  The urokinase receptor (u-PAR)--a link between tumor cell dormancy and minimal residual disease in bone marrow?

Authors:  Heike Allgayer; Julio A Aguirre-Ghiso
Journal:  APMIS       Date:  2008 Jul-Aug       Impact factor: 3.205

Review 5.  Tumor immunosurveillance in human cancers.

Authors:  Bernhard Mlecnik; Gabriela Bindea; Franck Pagès; Jérôme Galon
Journal:  Cancer Metastasis Rev       Date:  2011-03       Impact factor: 9.264

Review 6.  Review of tumor dormancy therapy using traditional oriental herbal medicine.

Authors:  Jong-Ho Lee; Fan-Pei Koung; Chong-Kwan Cho; Yeon-Weol Lee; Hwa-Seung Yoo
Journal:  J Pharmacopuncture       Date:  2013-03

Review 7.  The current paradigm and challenges ahead for the dormancy of disseminated tumor cells.

Authors:  Emma Risson; Ana Rita Nobre; Veronique Maguer-Satta; Julio A Aguirre-Ghiso
Journal:  Nat Cancer       Date:  2020-07-06

8.  Evasion of tumours from the control of the immune system: consequences of brief encounters.

Authors:  Mohannad Al-Tameemi; Mark Chaplain; Alberto d'Onofrio
Journal:  Biol Direct       Date:  2012-09-25       Impact factor: 4.540

9.  Platelet proteome and tumor dormancy: can platelets content serve as predictive biomarkers for exit of tumors from dormancy?

Authors:  Nava Almog; Giannoula Lakka Klement
Journal:  Cancers (Basel)       Date:  2010-05-11       Impact factor: 6.639

10.  The Role of Regulatory B Cell-Like Malignant Cells and Treg Cells in the Mouse Model of BCL1 Tumor Dormancy.

Authors:  Andrew BitMansour; Laurentiu M Pop; Ellen S Vitetta
Journal:  PLoS One       Date:  2016-12-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.